"Molecular remodeling of ion channels, exchangers and pumps in atrial and ventricular myocytes in ischemic cardiomyopathy
whole-tissue level. Different cell types remodel in the development and disease following their unique program. Moreover, this remodeling is anatomically heterogeneous. To overcome these problems and characterize ICM-induced molecular remodeling in a cell-type and anatomical region-specific fashion, we combined two technological innovations, laser-capture microdissection of cells of interest and microarray optimized for detection of alternative RNA splicing events in a narrow catalog of genes coding for ion channels, exchangers and pumps (CE&P genes), which comprise the most acclaimed target classes for top-selling prescription drugs. Because CE&P molecules are involved in electrical, signaling and mechanical functions of the heart, their remodeling in ICM may result in decreased cardiac contractile functions. 4 It is likely that pathophysiological conditions of ICM affect regulation of expression of CE&P splice variants. 5 Thus, existing molecular knowledge base of cardiovascular diseases is rudimentary because of lack of specific attribution to cell type and function. The aim of this study was to investigate cell-specific molecular remodeling in human atrial and ventricular myocytes associated with ischemic cardiomyopathy. Our strategy combines two technological innovations, laser-capture microdissection of identified cardiac cells in selected anatomical regions of the heart and splice microarray of a narrow catalog of the functionally most important genes regulating ion homeostasis. We focused on expression of a principal family of genes coding for ion channels, exchangers and pumps (Ce&p genes) that are involved in electrical, mechanical and signaling functions of the heart and constitute the most utilized drug targets. We found that (1) Ce&p genes remodel in a cell-specific manner: ischemic cardiomyopathy affected 63 Ce&p genes in ventricular myocytes and 12 essentially different genes in atrial myocytes. (2) Only few of the identified Ce&p genes were previously linked to human cardiac disfunctions. ( 3) The ischemia-affected Ce&p genes include nuclear chloride channels, adrenoceptors, cyclic nucleotide-gated channels, auxiliary subunits of Na + , K + and Ca 2+ channels, and cell-surface Ce&ps. (4) In both atrial and ventricular myocytes ischemic cardiomyopathy reduced expression of CACNG7 and induced overexpression of FXYD1, the gene crucial for Na + and K + homeostasis. Thus, our cell-specific molecular profiling defined new landmarks for correct molecular modeling of ischemic cardiomyopathy and development of underlying targeted therapies.
different CE&P subsets and only four indicated genes may be common among the ones affected by these diseases, overexpression of FXYD1 being the most obvious characteristic feature.
Discussion
Our study is based on the precept that to characterize the ICMinduced molecular remodeling it is essential to investigate it at the level of cells and molecules responsible for altered cardiac function. To achieve this goal, we developed the investigative approach combining laser capture microdissection of identified cardiac cells from tissue biopsies with splice microarray of custom-narrowed sets of CE&P genes that play ultimate role in cardiac contraction targeted by ICM. Our approach for the first time enabled direct comparison of altered gene expression caused by ICM in atrial and ventricular myocytes and identified new essential players.
First of all, we found that atrial and ventricular myocytes remodel following their unique programs where ICM affects different CE&P genes. Although some of these genes were already reported to be expressed in the heart 4, 79 (see also refs. in Tables  3 and 4) , only few of them were previously linked to known cardiac pathologies. 21, 39, 64, [80] [81] [82] [83] [84] These include (1) α 1B , α 2C and β 1 -adrenoceptors whose downregulation in cardiomyopathy was linked to pathological remodeling in failing ventricular myocardium. 42, 51, 85 (2) KCND2. In diabetic ventricle, a switch from K V 4.2 to K V 1.4 may underlie the slower kinetics of the I to K + current. 40 (3) KCND3. Downregulation of cardiac K V 4.3 and minK channels may be associated with arrhythmia and atrial fibrillation. 14, 61, 62, 86 It was reported that congestive heart failure and hypertrophy decrease K V 4.3 expression in terminally failing human hearts. 87 In line with this finding, KCND3 gene transfer abrogates the hypertrophic response to aortic stenosis. 88 (4) HCN2. Transfer of this gene was also tested as gene therapy for cardiac arrhythmias in experimental animals with positive results. 89 However, the existing knowledge base remains rudimentary in the absence of attribution to certain cardiac cell types and functions.
We found that ICM does not alter expression of Ca V 1.2 and Na V 5 channel isoforms and Na + ,K + -ATPase but rather affects some of their accessory subunits. The most profound change in both atrial and ventricular myocytes was overexpression of phospholemman. Binding of phospholemman to Na + ,K + -ATPase induces a decrease in the affinity of α1-β1 and α2-β1 isozymes to external K + and approximately 2-fold decrease in the affinity to internal Na + . 90 Inhibition of Na + /Ca 2+ exchanger by phospholemman 91 may add to the disbalance of Na + , K + and Ca 2+ gradients across the plasma membrane and contribute to hypertrophy of ICM muscle cells due to overexpression of FXYD1. Another unexpected finding that may have profound functional consequences is underexpression of Na V β1. Although the functional role of this single-membrane-spanning-repeat protein in the heart remains uncertain, it co-localizes with the Na V 1.5 pore-forming α1 subunit in the T-tubule system and intercalating discs levels in cardiomyocytes 17 and modulates Na V 1.5 channels in the heart by increasing the Na + current density. 92 Confirming its crucial role in the heart, SCN1B knock-out caused prolongation of QT and RR intervals 93 molecular profiling of disease-induced CE&P remodeling may narrow the search for crucial players and enable better understanding of underlying disease mechanisms and effective ICM prevention and treatment. We focused our research on CE&P molecular remodeling in atrial and ventricular cardiomyocytes because of their ultimate role in cardiac contraction targeted by ICM. This research strategy addressed the complexity of cardiovascular system and tissue heterogeneity complicated by differential gene expression and splice variation. Our findings associate ICM with altered expression of CACNG7 and FXYD1 in atrial and ventricular myocytes and show that these cells remodel in ICM following their unique programs involving different subsets of CE&P genes.
Results
Laser capture microdissection is an established method for isolation with confidence of histochemically identified cells from heterogeneous cell populations allowing the rational design of comprehensive splice variant profiling of CE&P remodeling in cardiomyocytes. Results of microarray analysis are presented in Table 3 and summarized in Table 4 . We found that ICM caused remodeling of 12 genes in atrial myocytes. Increased expression in relation to healthy hearts was found for the FXYD1 gene coding for protein regulator of Na + ,K + -ATPase phospholemman (2.3-fold) and intracellular chloride channels CLIC1 and CLIC4 (both 1.6-fold). The other nine identified genes were significantly downregulated including FXYD7, the inward rectifier K ir 2.4 channel, the acetylcholine receptor α10 subunit, the Ca 2+ channel Ca v γ subunits, the AMPA-selective glutamate receptor 3, the K V 4.3 K + channel involved in initial phase of repolarization and setting the plateau voltage of the action potential, the polyunsaturated fatty acids-activated and mechano-sensitive K 2P 4.1 channel, the Na + channel Na V β1 subunit. In ventricular myocytes we identified 63 genes affected by ICM. An increase (2.5-fold) was found only for FXYD1. The other 62 CE&P genes were downregulated 1.5-3.5 fold. Some of them belong to the same functional groups that are affected by ICM in atrial myocytes (Table 4) including FXYD3, three A-type K + channels, two inward rectifiers, three tandem-pore-domain K + channels, three Ca V γ subunits, six acetylcholine receptor subunits, and the AMPA1 glutamate receptor. In addition, we identified three delayed rectifiers, the Ca 2+ -activated K Ca 3.1 channel, seven modifiers and β-subunits of K + channels, six voltage-gated Ca 2+ channels, two ENaC and trp channels, cyclic nucleotide-gated channels HCN2 and CNGA3, three connexins, NMDA and glycine receptors, GABA receptor subunits and three adrenoceptors.
To find out whether the splice microarray results reported in Table 3 are disease-type specific, we supplemented the same splice microarray of ICM ventricular myocytes with one additional sample prepared from left ventricle of a 41-years old dilated cardiomyopathy male donor. The top-list ANOVA gene score annotation for combined altered CE&P genes in ventricular myocytes ( Table 3 ) was reduced from 63 to just 4 genes (FXYD1 (G fold = +2.4), HCN2 (-1.5), GLRA1 (-1.8) and GJC1 (-2.3)). This result suggests that dilated and ischemic cardiomyopathy may affect in St. Louis, MO. Healthy hearts were excluded from transplantation after exceeding 6 h-limit of allograft ischemic time. Showing no evidence of hemorrhagic stroke, they retained normal structure and function evidenced by bimodal biophotonic imaging and optical mapping of the atrioventricular junction. 100 There was no delay in collecting donor's heart tissue. Decision on suitability for transplantation was made prior to harvest of organs, our team members were notified in advance (at least 2 h before cross clamping) and were present during organ harvest. Heart was cardioplegically arrested, harvested and transferred to us immediately after removal from the chest. Tissue samples (0.5-2 g) were dissected from the area outside of scar burden (if any) of left ventricle and left atrial appendages under cold cardiopledic arrest conditions within approximately 30-40 min after removal of the heart from donor's chest. Tissue was washed in 4°C saline, immersed in Tissue-Tek OCT Compound (Electron Microscopy Sciences, Hatfield, PA), flash frozen in liquid nitrogen and stored at -80°C until use. Although availability of donors suitable for this study was limited, the number of selected human hearts ( Tables 1 and 2 ) is in full compliance with the NCBIrecommended MIAME guidelines to microarray 101 and enabled us to analyze all individual donor's samples, grouped by cell type, simultaneously on one microarray slide, thus excluding possible slide-to-slide variations.
Laser-capture microdissection and isolation of mRNA. Serial cryostat sections (7-8 µm thick) were cut from the frozen tissue samples using Minotome Plus microtome cryostat. Before lasercapture microdissection, cardiomyocytes in the sections were quickly (10 s) stained with Eosin Y (Sigma-Aldrich, St. Louis, MO) according to standard procedure. Given the notably large size of cardiac muscle cells relative to other cells in the tissue, this method of identification is sufficient to distinguish stained cardiomyocytes from other cells under microscope. Laser-capture microdissection was performed with PixCell II system (Arcturus, Mountain View, CA) using a 7.5-µm laser spot as described earlier. 5 The excised cardiomyocytes were picked up from the slide and development of cardiomyopathy. 94 Post-transcriptional gene silencing of Na V β1 reduced mRNA and protein levels of Na V 1.5, KChIP2 mRNA and K V 4.3 resulting in markedly decreased Na + and I to currents. 95 Thus, underexpression of Na V β1 may lead to a suppression of I to , action potential prolongation and increased susceptibility of the heart to ventricular arrhythmia.
Other new potential targets for drug discovery are CLICs. 8, 35 Members of the p64 family, CLIC proteins localize to the cell nucleus and exhibit both nuclear and plasma-membrane chloride channel activity, but their functions are not well defined. CLIC2, which shares sequence similarity with CLIC1, modulates cardiac ryanodine receptors and inhibits Ca 2+ release from the sarcoplasmic reticulum. 96 Thus, ICM-induced remodeling of CLICs in cardiomyocytes may affect membrane potential, intracellular pH and cell volume.
The four identified Ca V γ calcium channel subunits downregulated in ICM show a broad spectrum of modulating activities that may have a role in cardiac myocytes. The γ7, which is homologous to γ5, regulates stability of certain mRNAs 97 and, along with γ2 and γ8, controls trafficking and gating of AMPA receptors. 98, 99 It remains to be studied whether remodeling of AMPA receptors in ICM is associated with Ca V γs. Acetylcholine, 72 AMPA and NMDA receptors, 73 also downregulated in ICM, are present in cardiac neuromuscular junctions and intercalating disk, but little is known about their non-neuronal expression and roles in the heart.
Our study is the first step in molecular characterization of ICM with organ-and cell-specific annotation of altered expression of CE&P genes. Our study does not determine whether upregulation or downregulation of the identified CE&P genes are the primary drivers of ICM or reflect pathophysiological response to the disease. However, it provides an objective context within which it would be easier to find therapeutic targets among the elucidated markers of ICM. Future extension of this study may clarify links between CE&P genes expression and drug therapy, duration of disease, age, gender and race as potential factors in ICM and define key aspects of the principal gene network in relation to the development of ICM at the cellular and specific intercellular levels. In conjunction with protein and immunohistochemical analyses this may yield a more robust approach to better understanding mechanisms and pathophysiology of ICM-a critical need in the clinical utilization of this field.
Methods
Human cardiac tissue samples. Healthy (Table 1 ) and ICM hearts ( Table 2 ) of anonymous donors were obtained from the Cardiac Transplantation Center at the Washington University surface and captured on LCM Caps. To confirm the quality of cell isolation, the sectional images taken before and after microdissection were thoroughly inspected to exclude contamination with non-muscle cells, and only then the captured samples from serial sections were joined together. High-quality cellular RNA was recovered from the collected cells using PicoPure TM RNA isolation kit (Arcturus) and treated with RNase-free DNase (Qiagen, Valencia, CA). Quality of RNA was tested right before the labeling for microarray by measuring the OD and 28S/18S Microarray data analysis. The statistically significant differential expression patterns between ICM and healthy atrial and ventricular cell samples was analyzed using long-to short-form ratio statistics and expression level statistics to identify genes and splice events affected by ICM. All analyses were performed at ExonHit using Partek Genomics Suite. Principal Component Analysis was carried out to illustrate the level of spread between samples and experimental groups. A two-way ANOVA model was used to perform statistical tests on the probe set level intensities, to compare ICM vs. healthy cells. A Source of Variation plot was generated from this data to find the relative level of difference contributed by each factor. A cutoff level was determined to generate "top hit lists" of probe sets that indicate the most statistically significant differences between the sample groupings. The raw and transformed data sets are submitted to Gene Expression Omnibus, accession # GSE17294 and GSE17530. The method accounted for specific splice variants shown in the results, but did not evaluate the ICM-induced changes in alternative splicing. Low variability between the individual RNA samples in meaningful (p < 0.01) probesets, estimated as average of individual probesets standard deviations normalized to the respective mean values (0.08 ± 0.04, mean ± st.dev), suggests that differences in RNA ratios. On average, the OD ratio at 260/280 nm and 260/230 nm was >1.8 and the ratio of 28S/18S in the RNA samples selected for experiments was ≥1.6. Individual samples of total RNA were optionally amplified without 3'-bias using the TransPlex TM Whole Transcriptome Amplification kit (Rubicon Genomics, Ann Arbor, MI). (The non-bias 3'-amplification was confirmed by the automated RT-PCR with capillary electrophoretic quantification of amplicons executed on a commercial human cardiac total RNA samples (Sigma) with primers to CACNA1C and CACNB2, calcium channel genes characterized by complex alternative splicing). The amplified products were purified using QIAquick PCR purification kit (Qiagen).
cDNA labeling and microarray. The PCR products were fragmented with DNase I, denatured and end-labeled with Cy-3 fluorescent dye. The individual donor's samples, grouped according to cell type, were analyzed simultaneously on Human Ion Channel Splice Arrays 8-pack 4 x 44K slides (ExonHit Therapeutics, Gaithersburg, MD) manufactured on the Ion Channel Splice Array sv1.1 platform representing 287 human CE&P, including 248 alternatively spliced ones in total 1,655 splicing events and supplemented with additional capabilities to recognize connexins and ryanodine receptors. α1 (CHRNA1), α4 (CHRNA4), α6 (CHRNA6), α9 (CHRNA9), β3 (CHRNB3), δ (CHRND) 34 Glycine receptor α1 (GLRA1), α3 (GLRA3)
GABA receptor α3 (GABRA3) * , γ1 (GABRG1), γ2 (GABRG2), rho (GABRR1)
NMDA receptor receptor 73, 74 2A (GRIN2A), 2D (GRIN2D)
Glutamate receptor receptor 73, 74 AMpA3 (GRIA3) *13 AMpA1 (GRIA1), δ2 (GRID2) 
